News

Median PFS was 13.3 months in the ide-cel arm, compared to 4.4 months for the SOC arm.

The locum consultant of pediatric BMT and leukemia at Royal Manchester Children’s Hospital discussed the limited distribution model of arsa-cel in Europe.

Patients with large B-cell lymphoma had an ORR of 68% and a CR rate of 53%.

No adverse events related to RP-L201 have been reported to date.

Among the 14 patients with relapsed/refractory mantle cell lymphoma who were treated with LV20.19 CAR in the trial, the overall response at 28 days post-treatment was 100%.

Long-term hematologic stability has been observed in at least 6 out of 10 patients with at least 12 months of follow-up.

The associate professor of medicine at Medical College of Wisconsin discussed trials assessing the dual, CD19/CD20-targeting CAR T therapy.

Among 43 patients who had EBV+ PTLD following allogeneic hematopoietic cell transplant or solid organ transplant, the overall response rate was 51.2%.

Neither patient treated with RP-L301 required RBC transfusions at any point post-engraftment.

Antiviral responses increased until peaking at week 24.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A third price model to be tested will limit the price of generic drugs for chronic conditions to $2 under Medicare plan D.

Based on 4-week follow-up data from the first patient, an independent safety evaluation committee approved the trial’s continuation.

CT103A recently demonstrated safety in a phase 1 trial treating participants with NMOSD.

An independent DSMB has also recommended continued enrollment in the trial’s first cohort.

Progression free survival and overall response rate were higher in patients with R/R MM treated with Abecma than those treated with standard of care.

No serious adverse events deemed related to RGX-314 occurred in the treated patients.

Encouraging efficacy signals have also been observed in treated participants.

Significant reductions in pain were reported for patients who received rexlemestrocel-L+HA in comparison to patients who received a saline control.

The trial will take place at the University of Miami Health System and will be carried out in collaboration with the Diabetes Research Institute.

The professor and director of the Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center at University of Washington School of Medicine discussed the paper he recently coauthored.

Review top news and interview highlights from the week ending February 10, 2023.

The updated data included a median overall survival of 26 months after treatment with brexu-cel.

The latest data set includes 22 newly evaluable patients with triple-refractory disease.

The POLARIS study adds to the growing body of evidence validating GPRC5D as a target for CAR T-cell therapy in R/R MM.

Mehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.

The FDA cleared Century’s IND for CNTY-101 in August 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.